Prevention and the Agency for Toxic Substances and Disease Registry.

#### Claudette Grant,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2015–08521 Filed 4–13–15; 8:45 am] BILLING CODE 4163–18–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Centers for Disease Control and Prevention

## Board of Scientific Counselors, Office of Infectious Diseases, BSC, OID

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee:

*Time and Date:* 8:00 a.m.–5:00 p.m., EDT, May 6, 2015.

Place: CDC, Global Communications Center, 1600 Clifton Road NE., Building 19, Auditorium B3, Atlanta, Georgia 30333.

Status: The meeting is open to the public, limited only by the space available.

Purpose: The BSC, OID, provides advice and guidance to the Secretary, Department of Health and Human Services; the Director, CDC; the Director, OID; and the Directors of the National Center for Immunization and Respiratory Diseases, the National Center for Emerging and Zoonotic Infectious Diseases, and the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, in the following areas: Strategies, goals, and priorities for programs; research within the national centers; and overall strategic direction and focus of OID and the national centers.

Matters for Discussion: The meeting will include a report from the Food Safety Modernization Act Surveillance Working Group of the BSC, OID; brief updates on priority issues for CDC's infectious disease programs; and updates and discussions on CDC's Surveillance Strategy and the Global Health Security Agenda.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Robin Moseley, M.A.T., Designated Federal Officer, OID, CDC, 1600 Clifton Road NE., Mailstop D10, Atlanta, Georgia 30333, Telephone: (404) 639– 4461.

The Director, Management Analysis and Services Office has been delegated

the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

### Claudette Grant,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2015-08518 Filed 4-13-15; 8:45 am]

BILLING CODE 4163-18-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Centers for Disease Control and Prevention

## Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP); Initial Review

The meeting announced below concerns Comparison and Validation of Screening Tools for Substance Use Among Pregnant Women, DP15–003, initial review.

**SUMMARY:** This document corrects a notice that was published in the **Federal Register** on March 12, 2015 Volume 80, Number 48, page 13011. The times and dates should read as follows:

Times and Dates: 9:00 a.m.-6:00 p.m., April 7–8, 2015 (Closed).

# FOR FURTHER INFORMATION CONTACT: M. Chris Langub, Ph.D., Scientific Review Officer, CDC, 4770 Buford Highway NE., Mailstop F46, Atlanta, Georgia 30341, Talaphone: (770)488–3585, FEOGO

Telephone: (770)488–3585, *EEO*6@ *cdc.gov.* 

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

#### Claudette Grant,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2015–08519 Filed 4–13–15; 8:45 am] BILLING CODE 4163–18–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)

## Centers for Disease Control and Prevention

## Healthcare Infection Control Practices Advisory Committee (HICPAC)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announce the following meeting for the aforementioned committee:

*Time and Date:* 2:00 p.m.–3:00 p.m., EST, May 11, 2015.

*Place:* This meeting will be accessible by teleconference. Toll-free +1 (888) 790–1864, Participant Code: 5920580.

*Status:* Open to the public limited only by the availability of telephone ports.

Purpose: The Committee is charged with providing advice and guidance to the Director, Division of Healthcare Quality Promotion, the Director, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), the Director, CDC, the Secretary, Health and Human Services regarding (1) the practice of healthcare infection prevention and control; (2) strategies for surveillance, prevention, and control of infections, antimicrobial resistance, and related events in settings where healthcare is provided; and (3) periodic updating of CDC guidelines and other policy statements regarding prevention of healthcare-associated infections and healthcare-related conditions.

Matters for Discussion: The agenda will include a follow up discussion on the Draft Guideline for the Prevention of Surgical Site Infections. Call materials will be made available to the public no later than 2 business days before the call. If CDC is unable to post the background material on the HICPAC site prior to the meeting, the background material will be posted on HICPAC's Web site after the meeting. Background material is available at http://www.cdc.gov/hicpac.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Erin Stone, M.S., HICPAC, Division of Healthcare Quality Promotion, NCEZID, CDC, 1600 Clifton Road NE., Mailstop A–31, Atlanta, Georgia 30333; Email: HICPAC@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and